Insulet (PODD) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Insulet Revenue Highlights

Latest Revenue (Y)

$1.70B

Latest Revenue (Q)

$372.60M

Main Segment (Y)

Product, Omnipod

Main Geography (Y)

UNITED STATES

Insulet Revenue by Period

Insulet Revenue by Year

Date	Revenue	Change
2023-12-31	$1.70B	30.02%
2022-12-31	$1.31B	18.79%
2021-12-31	$1.10B	21.49%
2020-12-31	$904.40M	22.51%
2019-12-31	$738.20M	30.93%
2018-12-31	$563.82M	21.57%
2017-12-31	$463.77M	26.37%
2016-12-31	$366.99M	39.07%
2015-12-31	$263.89M	-8.60%
2014-12-31	$288.72M	16.85%
2013-12-31	$247.08M	16.90%
2012-12-31	$211.37M	38.83%
2011-12-31	$152.25M	57.02%
2010-12-31	$96.97M	46.85%
2009-12-31	$66.03M	83.12%
2008-12-31	$36.06M	169.66%
2007-12-31	$13.37M	265.06%
2006-12-31	$3.66M	7226.00%
2005-12-31	$50.00K	100.00%
2004-12-31	-	100.00%
2003-12-31	-	100.00%
2002-12-31	-	-

Insulet generated $1.70B in revenue during NA 2023, up 30.02% compared to the previous quarter, and up 301.00% compared to the same period a year ago.

Insulet Revenue by Quarter

Date	Revenue	Change
2024-09-30	$372.60M	-23.73%
2024-06-30	$488.50M	10.60%
2024-03-31	$441.70M	-13.36%
2023-12-31	$509.80M	17.82%
2023-09-30	$432.70M	9.13%
2023-06-30	$396.50M	10.72%
2023-03-31	$358.10M	-3.14%
2022-12-31	$369.70M	8.48%
2022-09-30	$340.80M	13.83%
2022-06-30	$299.40M	1.35%
2022-03-31	$295.40M	-4.00%
2021-12-31	$307.70M	11.65%
2021-09-30	$275.60M	4.71%
2021-06-30	$263.20M	4.32%
2021-03-31	$252.30M	2.52%
2020-12-31	$246.10M	5.17%
2020-09-30	$234.00M	3.40%
2020-06-30	$226.30M	14.29%
2020-03-31	$198.00M	-5.44%
2019-12-31	$209.40M	9.00%
2019-09-30	$192.12M	8.46%
2019-06-30	$177.14M	11.02%
2019-03-31	$159.56M	-3.25%
2018-12-31	$164.91M	9.15%
2018-09-30	$151.08M	21.58%
2018-06-30	$124.26M	0.55%
2018-03-31	$123.58M	-5.32%
2017-12-31	$130.52M	7.18%
2017-09-30	$121.78M	10.95%
2017-06-30	$109.76M	7.91%
2017-03-31	$101.71M	-1.80%
2016-12-31	$103.58M	9.17%
2016-09-30	$94.87M	8.64%
2016-06-30	$87.33M	7.53%
2016-03-31	$81.21M	-18.88%
2015-12-31	$100.12M	14.68%
2015-09-30	$87.30M	15.50%
2015-06-30	$75.59M	23.48%
2015-03-31	$61.22M	-15.64%
2014-12-31	$72.56M	-3.23%
2014-09-30	$74.98M	4.13%
2014-06-30	$72.01M	4.12%
2014-03-31	$69.16M	0.92%
2013-12-31	$68.53M	12.16%
2013-09-30	$61.10M	1.68%
2013-06-30	$60.09M	4.77%
2013-03-31	$57.36M	-0.82%
2012-12-31	$57.83M	5.62%
2012-09-30	$54.75M	7.28%
2012-06-30	$51.03M	6.87%
2012-03-31	$47.75M	1.19%
2011-12-31	$47.19M	5.83%
2011-09-30	$44.59M	38.44%
2011-06-30	$32.21M	13.99%
2011-03-31	$28.26M	1.77%
2010-12-31	$27.77M	9.08%
2010-09-30	$25.45M	10.98%
2010-06-30	$22.94M	10.24%
2010-03-31	$20.81M	2.95%
2009-12-31	$20.21M	7.88%
2009-09-30	$18.73M	28.17%
2009-06-30	$14.62M	17.23%
2009-03-31	$12.47M	5.13%
2008-12-31	$11.86M	17.32%
2008-09-30	$10.11M	36.31%
2008-06-30	$7.42M	11.18%
2008-03-31	$6.67M	52.97%
2007-12-31	$4.36M	-

Insulet generated $372.60M in revenue during Q3 2024, up -23.73% compared to the previous quarter, and up 93.97% compared to the same period a year ago.

Insulet Revenue Breakdown

Insulet Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Product, Omnipod	$1.66B	$1.25B	$1.01B	$834.90M	$673.50M
International Omnipod	$410.10M	$363.00M	$359.90M	$308.00M	$253.10M
Drug Delivery	$36.00M	$57.50M	$87.40M	$69.50M	$64.70M
U.S. Omnipod	$1.25B	$884.80M	$651.50M	$526.90M	$420.40M

Insulet's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product, Omnipod (49.46%), U.S. Omnipod (37.25%), International Omnipod (12.21%), and Drug Delivery (1.07%).

Quarterly Revenue by Product

Product/Service	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
International Omnipod	$533.60M	$433.00M	$106.40M	$101.40M	$103.70M	$98.60M	$90.20M	$88.00M	$89.40M	$95.40M	$85.30M	$93.10M	$91.60M	$89.90M	$81.90M	$79.80M	$73.20M	$73.10M	$65.72M	$67.75M
Drug Delivery	$10.30M	$8.70M	$8.80M	$10.70M	$16.00M	$500.00K	$3.30M	$14.70M	$13.60M	$25.90M	$31.90M	$15.30M	$21.10M	$19.10M	$15.00M	$21.90M	$24.30M	$8.30M	$16.91M	$14.90M
U.S. Omnipod	-	$317.70M	$394.60M	$320.60M	$276.80M	$259.00M	$276.20M	$238.10M	$196.40M	$174.10M	$190.50M	$167.20M	$150.50M	$143.30M	$149.20M	$132.30M	$128.80M	$116.60M	$126.76M	$109.46M
Product, Omnipod	-	$433.00M	$501.00M	$422.00M	$380.50M	$357.60M	$366.40M	$326.10M	$285.80M	$269.50M	$275.80M	$260.30M	$242.10M	$233.20M	$231.10M	$212.10M	$202.00M	$189.70M	-	-
Product, Diabetes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$177.22M

Insulet's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: International Omnipod (98.11%), and Drug Delivery (1.89%).

Insulet Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Non-US	$410.10M	$363.00M	$359.90M	$308.00M	$253.10M
UNITED STATES	$1.29B	$942.30M	$738.90M	$596.40M	$485.10M

Insulet's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (75.84%), and Non-US (24.16%).

Insulet Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
ABT	Abbott Laboratories	$40.11B	$10.63B
SYK	Stryker	$20.50B	$5.49B
EW	Edwards Lifesciences	$6.00B	$1.35B
ALGN	Align	$3.86B	$977.87M
DXCM	DexCom	$3.62B	$994.20M
MASI	Masimo	$2.05B	$504.60M
PODD	Insulet	$1.70B	$372.60M
IART	Integra LifeSciences	$1.54B	$380.83M
PEN	Penumbra	$1.06B	$301.04M
TNDM	Tandem Diabetes Care	$747.72M	$221.91M
INSP	Inspire Medical Systems	$624.80M	$203.19M
NARI	Inari Medical	$493.63M	$153.39M
INMD	InMode	$492.05M	$80.28M
GKOS	Glaukos	$314.71M	$96.67M
TMDX	TransMedics Group	$241.62M	$-12.24M

PODD Revenue FAQ

What is Insulet’s yearly revenue?

Insulet's yearly revenue for 2023 was $1.7B, representing an increase of 30.02% compared to 2022. The company's yearly revenue for 2022 was $1.31B, representing an increase of 18.79% compared to 2021. PODD's yearly revenue for 2021 was $1.1B, representing an increase of 21.49% compared to 2020.

What is Insulet’s quarterly revenue?

Insulet's quarterly revenue for Q3 2024 was $372.6M, a -23.73% decrease from the previous quarter (Q2 2024), and a -13.89% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $488.5M, a 10.60% increase from the previous quarter (Q1 2024), and a 23.20% increase year-over-year (Q2 2023). PODD's quarterly revenue for Q1 2024 was $441.7M, a -13.36% decrease from the previous quarter (Q4 2023), and a 23.35% increase year-over-year (Q1 2023).

What is Insulet’s revenue growth rate?

Insulet's revenue growth rate for the last 3 years (2021-2023) was 54.45%, and for the last 5 years (2019-2023) was 129.90%.

What are Insulet’s revenue streams?

Insulet's revenue streams in c 23 are Product, Omnipod, International Omnipod, Drug Delivery, and U.S. Omnipod. Product, Omnipod generated $1.66B in revenue, accounting 49.46% of the company's total revenue, up 33.12% year-over-year. International Omnipod generated $410.1M in revenue, accounting 12.21% of the company's total revenue, up 12.98% year-over-year. Drug Delivery generated $36M in revenue, accounting 1.07% of the company's total revenue, down -37.39% year-over-year. U.S. Omnipod generated $1.25B in revenue, accounting 37.25% of the company's total revenue, up 41.39% year-over-year.

What is Insulet’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Insulet was Product, Omnipod. This segment made a revenue of $1.66B, representing 49.46% of the company's total revenue.